CO6640213A2 - Comprimido de desintegración por vía oral que contiene acarbosa - Google Patents

Comprimido de desintegración por vía oral que contiene acarbosa

Info

Publication number
CO6640213A2
CO6640213A2 CO12192234A CO12192234A CO6640213A2 CO 6640213 A2 CO6640213 A2 CO 6640213A2 CO 12192234 A CO12192234 A CO 12192234A CO 12192234 A CO12192234 A CO 12192234A CO 6640213 A2 CO6640213 A2 CO 6640213A2
Authority
CO
Colombia
Prior art keywords
disintegration tablet
oral disintegration
tablet containing
acarbose
containing acarbose
Prior art date
Application number
CO12192234A
Other languages
English (en)
Inventor
Axel Schneeweis
Tobias Laich
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CO6640213A2 publication Critical patent/CO6640213A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Era un objeto de la presente invención proporcionar un comprimido de desintegración por vía oral (ODT) para el inhibidor de la glucosidasa acarbosa. El objetivo se consigue con un comprimido de desintegración por vía oral que contiene un 1-30 % de acarbosa y un 40-90 % de vehículo soluble en agua.Con el fin de obtener las propiedades deseadas, se tienen que compactar previamente los ingredientes y mezclar previamente con un vehículo insoluble.
CO12192234A 2010-04-27 2012-10-26 Comprimido de desintegración por vía oral que contiene acarbosa CO6640213A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10161114 2010-04-27

Publications (1)

Publication Number Publication Date
CO6640213A2 true CO6640213A2 (es) 2013-03-22

Family

ID=44344015

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12192234A CO6640213A2 (es) 2010-04-27 2012-10-26 Comprimido de desintegración por vía oral que contiene acarbosa

Country Status (26)

Country Link
US (1) US20130131003A1 (es)
EP (1) EP2563329B1 (es)
JP (1) JP5944378B2 (es)
KR (1) KR101788350B1 (es)
CN (2) CN106924199A (es)
AU (1) AU2011247642C1 (es)
BR (1) BR112012027303A2 (es)
CA (1) CA2797365A1 (es)
CL (1) CL2012003011A1 (es)
CO (1) CO6640213A2 (es)
CR (1) CR20120548A (es)
CU (1) CU20120152A7 (es)
DO (1) DOP2012000277A (es)
EC (1) ECSP12012279A (es)
ES (1) ES2623025T3 (es)
GT (1) GT201200290A (es)
IL (1) IL222368B (es)
MX (1) MX348865B (es)
MY (1) MY179724A (es)
NZ (1) NZ603199A (es)
PE (1) PE20130403A1 (es)
SG (2) SG184851A1 (es)
SI (1) SI2563329T1 (es)
TW (1) TWI556823B (es)
UA (1) UA111155C2 (es)
WO (1) WO2011134962A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201100150A2 (tr) * 2011-01-06 2012-07-23 Bi̇lgi̇ç Mahmut Suda çözünür dozaj formları
WO2013115741A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic Pharmaceutical compositions comprising alpha-glucosidase inhibitor
WO2013115738A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic Micronized acarbose
US9750705B2 (en) 2012-08-31 2017-09-05 The Regents Of The University Of California Agents useful for treating obesity, diabetes and related disorders
CN104013590A (zh) * 2014-05-09 2014-09-03 万特制药(海南)有限公司 一种含阿卡波糖的药物组合物及其制备方法
EP3943076A3 (en) 2014-12-17 2022-04-13 Empros Pharma AB A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
CN105213341A (zh) * 2015-10-29 2016-01-06 无锡福祈制药有限公司 一种阿卡波糖片及其制备方法
CN113081984B (zh) * 2021-04-19 2023-06-02 北京阳光诺和药物研究股份有限公司 一种阿卡波糖口崩片及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134591A1 (de) * 1981-09-01 1983-03-10 Bayer Ag, 5090 Leverkusen Neue arzneimittelpraeparationen fuer glykosidhydrolasen-inhibitoren
JPH10182687A (ja) * 1996-10-21 1998-07-07 Bayer Yakuhin Kk アカルボースの貯蔵安定化法
DE19802700A1 (de) * 1998-01-24 1999-07-29 Bayer Ag Verfahren zur Herstellung einer im Mund schnell zerfallenden Arzneiform, die als Wirkstoff Acarbose enthält
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
KR100682836B1 (ko) * 2004-12-06 2007-02-15 엘지전자 주식회사 유기 전계 발광 소자
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation
MY157620A (en) * 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
CN101390440B (zh) * 2006-02-27 2012-10-10 松下电器产业株式会社 可穿戴终端、控制可穿戴终端的处理器及方法
FI20070521L (fi) * 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
CN101411715B (zh) * 2007-10-19 2012-03-28 杭州华东医药集团生物工程研究所有限公司 含有阿卡波糖的药物组合物
JP5291324B2 (ja) * 2007-11-01 2013-09-18 沢井製薬株式会社 口腔内崩壊錠
JP2009114113A (ja) * 2007-11-06 2009-05-28 Nipro Corp 口腔内崩壊錠及びその製造方法
CN101888834A (zh) * 2007-12-08 2010-11-17 拜耳先灵制药股份公司 口服分散片
AR069875A1 (es) * 2007-12-21 2010-02-24 Eurand Inc Composiciones de temazepam para tabletas de desintegracion oral y metodo de preparacion
KR101647855B1 (ko) * 2008-06-20 2016-08-11 메르크 파텐트 게엠베하 직접 사출성형가능한 신속 붕해 정제 매트릭스

Also Published As

Publication number Publication date
CN102905687A (zh) 2013-01-30
WO2011134962A3 (en) 2012-05-03
CU20120152A7 (es) 2014-02-28
SG10201505844WA (en) 2015-09-29
CN106924199A (zh) 2017-07-07
EP2563329A2 (en) 2013-03-06
MX2012012459A (es) 2012-11-21
TWI556823B (zh) 2016-11-11
WO2011134962A2 (en) 2011-11-03
MX348865B (es) 2017-07-03
AU2011247642C1 (en) 2015-11-12
CL2012003011A1 (es) 2013-04-19
DOP2012000277A (es) 2012-12-15
NZ603199A (en) 2014-05-30
CR20120548A (es) 2013-03-11
SI2563329T1 (sl) 2017-05-31
BR112012027303A2 (pt) 2017-10-24
EP2563329B1 (en) 2017-04-12
GT201200290A (es) 2014-09-24
ES2623025T3 (es) 2017-07-10
IL222368B (en) 2018-11-29
JP5944378B2 (ja) 2016-07-05
KR101788350B1 (ko) 2017-10-19
SG184851A1 (en) 2012-11-29
KR20130062926A (ko) 2013-06-13
PE20130403A1 (es) 2013-04-13
MY179724A (en) 2020-11-11
UA111155C2 (uk) 2016-04-11
US20130131003A1 (en) 2013-05-23
CA2797365A1 (en) 2011-11-03
AU2011247642B2 (en) 2015-05-14
JP2013525404A (ja) 2013-06-20
IL222368A0 (en) 2012-12-31
ECSP12012279A (es) 2012-11-30
AU2011247642A1 (en) 2012-11-08
TW201141490A (en) 2011-12-01

Similar Documents

Publication Publication Date Title
CO6640213A2 (es) Comprimido de desintegración por vía oral que contiene acarbosa
GT201400196A (es) Compuestos de heterociclilo
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
AR077199A1 (es) Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia
NI201500167A (es) Compuestos químicos
GT201300137A (es) Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak
CO6771428A2 (es) Composición efervescente en forma sólida para uso en aplicaciones vaginales para el tratamiento de infecciones vaginales
GT201200165A (es) Triazolopiridinas
BR112012019529A2 (pt) inibidores de d-nitrosoglutationa redutase
BR112014004460A2 (pt) material polimérico para um recipiente isolado
DOP2015000170A (es) Compuestos químicos
UY34112A (es) Composiciones farmacéuticas que contienen un agente neuroléptico y un inhibidor sglt2 y usos de los mismos
AR081670A1 (es) Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
CO7091174A2 (es) Compuestos triazolo como inhibidores de pde10
BR112015008912A2 (pt) composições solidificáveis compreendendo volastonita e pedra-pomes e métodos de uso
BR112015030431A2 (pt) formulação de liberação modificada
BR112015027824A8 (pt) formulação de vitamina e na forma de pó
ECSP12011837A (es) Derivados de pirazol que modulan la estearoil-coa-desaturasa
AR089114A1 (es) PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3
CL2011000621A1 (es) Agente que contiene por lo menos un acido acilciclohexanodionacarboxilico y/o sus sales en combinacion con por lo menos un ester de acido acilciclohexanodionacarboxilico y su uso para mejorar el desarrollo de gramineas.
NI201300100A (es) Derivados de tieno [2, 3-d] pirimidina y su uso para tratar arritmias
CR20120461A (es) Hidrato del hidrobromuro de agomelatina y preparación de éste
CL2012001759A1 (es) Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica.
BR112013027391A2 (pt) formulação farmacêutica, frasco e kit
BR112012024239A2 (pt) composição para tratamento de trombocitemia essencial

Legal Events

Date Code Title Description
FC Application refused